In vitro evaluation of a new cefixime-clavulanic acid combination for gram-negative bacteria

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 40, Issue 1, 2009, Pages 131-139

  Rawat, Deepti ^a   Hasan, Azra S ^a   Capoor, Malini R ^a   Sarma, Smita ^a   Nair, Deepthi ^a,c   Deb, Monorama ^a   Pillai, Parukutty ^b   Aggarwal, Pushpa ^a  

^a SAFDARJUNG HOSPITAL   (India)

^b Majeedia Hospital   (India)

^c NONE   (India)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 59149101313     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Akram M, Shahid M, Khan AU. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in JNMC Hospital Aligarh, India. Ann Clin Microbiol Antimicrob 2007; 23: 4.
2. Bhattacharya S. ESBL-From petri dish to the patient. Indian J Med Microbiol 2006; 24: 20-4.
3. Calbo E, Romani V, Xercavins M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006; 57: 780-3.
4. Chaudhary U, Aggarwal R. Extended spectrum -lactamases (ESBL) - An emerging threat to clinical therapeutics. Indian J Med Microbiol 2004; 22: 75-80.
5. th Information Supplement. CLSI/ NCCLS Document M100-S16. Wayne, PA: Clinical and Laboratory Standards Institute, 2007.
6. Colodner R, Keness Y, Chazan B, Raz R. Antimicrobial susceptibility of community-acquired uropathogens in northern Israel. Int J Antimicrobial Agents 2001; 18: 189-92.
7. Doi Y, Adams J, O'Keefe A, Quereshi Z, Ewan L, Paterson DL. Community-acquired extended-spectrum beta-lactamase producers, United States [Letter]. Emerg Infect Dis [serial on the Internet] 2007. [Cited 2008 Mar 16]. Available from: URL: http://www.cdc.gov/EID/content/13/7/1121 .htm
8. Hryniewicz K, Szczypa K, Sulikowska A, Jankowski K, Betlejewska K, Hryniewicz W. Antibiotic susceptibility of bacterial strains isolated from urinary tract infections in Poland. J Antimicrob Chemother 2001; 47: 773-80.
9. Manchanda V, Singh NP. Occurrence and detection of AmpC beta-lactamases among Gram-negative clinical isolates using a modified three-dimensional test at Guru Tegh Bahadur Hospital, Delhi, India. J Antimicrobial Chemother 2003; 51: 415-8.
10. Mathai D, Rhomberg PR, Biedenbach DJ, Jones RN. India Antimicrobial Resistance Study Group: Evaluation of the in vitro activity of six broad-spectrum beta-lactam antimicrobial agents tested against recent clinical isolates from India: a survey of ten medical center laboratories. Diagn Microbiol Infect Dis 2002; 44: 367-77.
11. Mathur P, Kapil A, Das B, Dhawan B. Prevalence of extended spectrum beta lactamase producing gram negative bacteria in a tertiary care hospital. Indian J Med Res 2002; 115:153-7.
12. Mc Gowen. Resistance in nonfermenting gram-negative bacteria: Multidrug resistance to the maximum. Am J Infect Countr 2006; 34: S29-37.
13. Miriagou V, Tassios NT, Legakis NJ, Tzouvelekis LS. Expanded spectrum cephalosporin resistance in non-typhoid Salmonella. Int J Antimicrob Agents 2004; 23: 547-55.
14. Mohanty S, Kapil A, Dhawan B, Das BK. Bacteriological and antimicrobial susceptibility profile of soft tissue infections from Northern India. Indian J Med Sci 2004; 8: 10-5.
15. Mohanty S, Singhal R, Sood S, Dhawan B, Das BK, Kapil A. Comparative in vitro activity of beta-lactam/beta-lactamase inhibitor combinations against gram negative bacteria. Indian J Med Res 2005; 122: 425-8.
16. National Committee for Clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial susceptibility testing. NCCLS approved standard M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards, 1999.
17. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-86.
18. Pitout JDD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacteriaceae producing extended-spectrum β-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56: 52-9.
19. Pokhare BM, Koirala J, Dahal RK, Mishra SK, Khadga PK, Tuladhar NR. Multidrug-resis- tant and extended spectrum beta lactamase (ESBL) producing Salmonella enterica (serotypes typhi and paratyphi A) from blood isolates in Nepal: surveillance for resistance and a search for newer alternatives. Int J Infect Dis 2006; 10: 434-8.
20. Rodriguez-Bano JMD, Navarro L, Romero L, et al. Epidemiology and clinical features of infections caused by extended-spectrum beta-lactamase- producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
21. Singhal S, Mathur T, Khan S, et al. Evaluation of methods for AmpC beta-lactamase in gram negative clinical isolates from tertiary care hospitals. Indian J Med Microbiol 2005; 23: 120-4.
22. Supriya S, Tankhiwale S, Jalgaonkar V, Sarfraz Ahamad S, Hassani U. Evaluation of extended spectrum beta lactamase in urinary isolates. Indian J Med Res 2004; 20: 553-6.
23. Subha A, Ananthan S. Extended spectrum beta lactamase (ESBL) mediated resistance to third generation cephalosporins among Klebsiella pneumoniae in Chennai. Indian J Med Microbiol 2002; 20: 92-5.
24. Weill FX, Guesnier F, Guibert V, et al. Multidrug resistance in Salmonella enterica serotype Typhimurium from humans in France (1993-2003). J Clin Microbiol 2006; 44: 700-8.